Awards and honours

With colleagues, Marais received the American Association for Cancer Research (AACR) Team Science Award in 2012 for cancer drug discoveries.^[3] He received the Leopold Griffuel Prize in 2016^[3] and the Outstanding Research Award from the Society for Melanoma Research (SMR) in 2017.^[3] He was elected a member of the European Molecular Biology Organization (EMBO) in 2009,^[2] a Fellow of the Royal Society (FRS) in 2018,^[3] and a Fellow of the Academy of Medical Sciences (FMedSci) in 2008.^[7] His citation on election reads:

Richard Marais is Professor of Molecular Oncology at Cancer Research UK and has made important contributions to the understanding of cell signalling pathways, particularly in cancer. He was amongst the first to show that mitogen activated protein kinases regulate gene expression by directly phosphorylating transcription factors. However his greatest impact has been with the RAF kinase family, where he discovered that individual RAF proteins are regulated differentially and shown how they respond to RAS, which is mutated in a third of all human tumours. He was a key member of the team that demonstrated that B-RAF is encoded by an oncogene, which is a culprit in most human melanomas. He went on to validate B-RAF as a therapeutic target. In collaboration with David Barford, he solved the crystal structure of B-RAF and explained how it is activated by mutations that occur in cancer. He elucidated why C-RAF is not mutated in cancer, showing that mutant forms of B-RAF can activate C-RAF through a novel mechanism, establishing a new paradigm of RAF signaling. He is now translating these studies to the clinic by leading a large effort to design and synthesize new anti-B-RAF drugs that will be used to treat melanoma.^[7]

Marais was awarded membership of the Academia Europaea (MAE) in 2015.^[8]